Cellectis , a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells announces today the sale of its subsidiary Cellectis AB to the Japanese Company Takara Bio Inc. This operation, which will be realized in the coming weeks subject to the completion of certain usual conditions, is for Cellectis the ... (more)
http://ift.tt/1nBUvoe
http://ift.tt/1nBUvoe
No comments:
Post a Comment